» Articles » PMID: 37488783

Prevalence and Determinants of Hepatitis Delta Virus Infection Among HIV/hepatitis B-coinfected Adults in Care in the United States

Abstract

Hepatitis delta virus (HDV) infection increases the risk of liver complications compared to hepatitis B virus (HBV) alone, particularly among persons with human immunodeficiency virus (HIV). However, no studies have evaluated the prevalence or determinants of HDV infection among people with HIV/HBV in the US. We performed a cross-sectional study among adults with HIV/HBV coinfection receiving care at eight sites within the Center for AIDS Research Network of Integrated Clinical Systems (CNICS) between 1996 and 2019. Among patients with available serum/plasma specimens, we selected the first specimen on or after their initial HBV qualifying test. All samples were tested for HDV IgG antibody and HDV RNA. Multivariable log-binomial generalized linear models were used to estimate prevalence ratios (PRs) with 95% CIs of HDV IgG antibody-positivity associated with determinants of interest (age, injection drug use [IDU], high-risk sexual behaviour). Among 597 adults with HIV/HBV coinfection in CNICS and available serum/plasma samples (median age, 43 years; 89.9% male; 52.8% Black; 42.4% White), 24/597 (4.0%; 95% CI, 2.4%-5.6%) were HDV IgG antibody-positive, and 10/596 (1.7%; 95% CI, 0.6%-2.7%) had detectable HDV RNA. In multivariable analysis, IDU was associated with exposure to HDV infection (adjusted PR = 2.50; 95% CI, 1.09-5.74). In conclusion, among a sample of adults with HIV/HBV coinfection in care in the US, 4.0% were HDV IgG antibody-positive, among whom 41.7% had detectable HDV RNA. History of IDU was associated with exposure to HDV infection. These findings emphasize the importance of HDV testing among persons with HIV/HBV coinfection, especially those with a history of IDU.

Citing Articles

Prevalence of Hepatitis D in People Living with HIV: A National Cross-Sectional Pilot Study.

Schinas G, Antonopoulou N, Vamvakopoulou S, Tsachouridou O, Protopapas K, Petrakis V Viruses. 2024; 16(7).

PMID: 39066206 PMC: 11281684. DOI: 10.3390/v16071044.

References
1.
Thio C, Seaberg E, Skolasky Jr R, Phair J, Visscher B, Munoz A . HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002; 360(9349):1921-6. DOI: 10.1016/s0140-6736(02)11913-1. View

2.
Wedemeyer H, Manns M . Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010; 7(1):31-40. DOI: 10.1038/nrgastro.2009.205. View

3.
Hughes S, Wedemeyer H, Harrison P . Hepatitis delta virus. Lancet. 2011; 378(9785):73-85. DOI: 10.1016/S0140-6736(10)61931-9. View

4.
Kim H, Newcomb C, Carbonari D, Roy J, Torgersen J, Althoff K . Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America. Hepatology. 2021; 74(3):1190-1202. PMC: 8843101. DOI: 10.1002/hep.31839. View

5.
Arribas J, Gonzalez-Garcia J, Lorenzo A, Montero D, Ladron de Guevara C, Montes M . Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain. AIDS. 2005; 19(13):1361-5. DOI: 10.1097/01.aids.0000180787.10553.b2. View